MedElevator Войти в исследования
← Поиск публикаций

DOI 10.2967/jnumed.125.271459

Медицинская библиотека · Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026

Feasibility of [89Zr]Zr-Atezolizumab Immuno-PET for PD-L1 Quantification in the Clinical Work-up of Metastatic Triple-Negative Breast Cancer.

Nijveldt Joni J, Af Burén Siri, Tran Thuy A, Jussing Emma, Nilsson Joachim N, Kistner Anna, Axelsson Rimma, Bergh Jonas, Hartman Johan, Tzortzakakis Antonios, Altena Renske

СтатьяНаблюдательное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Immune checkpoint inhibitors combined with chemotherapy are established as first-line therapy for patients with programmed death ligand 1 (PD-L1)-positive metastatic triple-negative breast cancer (mTNBC). We evaluated whether immuno-PET using [89Zr]Zr-atezolizumab could more accurately identify patients with mTNBC who may benefit from immune checkpoint inhibitor therapy.

Methods

Three patients with mTNBC underwent [89Zr]Zr-atezolizumab PET/CT followed by a biopsy of a targeted metastatic lesion. Patients received atezolizumab plus chemotherapy if either immunohistochemistry of the metastatic lesion or PET imaging showed PD-L1 positivity.

Results

All patients had tracer-avid metastatic lesions on PET. Two of 3 biopsied, tracer-avid lesions were PD-L1 negative on immunohistochemistry. Intraindividual heterogeneity in tracer uptake was noted. All patients were treated with atezolizumab plus chemotherapy, with all demonstrating an initial response.

Conclusion

A work-up with [89Zr]Zr-atezolizumab immuno-PET is clinically feasible. This molecular imaging-based strategy holds potential as a noninvasive tool to more accurately identify patients with mTNBC who may benefit from immune checkpoint inhibitor therapy.

Для цитирования: Nijveldt Joni J, Af Burén Siri, Tran Thuy A, Jussing Emma, Nilsson Joachim N, Kistner Anna, Axelsson Rimma, Bergh Jonas, Hartman Johan, Tzortzakakis Antonios, Altena Renske. Feasibility of [89Zr]Zr-Atezolizumab Immuno-PET for PD-L1 Quantification in the Clinical Work-up of Metastatic Triple-Negative Breast Cancer.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2026. DOI: 10.2967/jnumed.125.271459.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.